OBN BioTuesday: A Spotlight on Oncology Precision Prevention Treatments and the Expected Impact on People with High-Risk Conditions
This edition of our ever popular BioTuesday event will provide 'OBN BioTuesday: A Spotlight on Oncology Precision Prevention Treatments and the Expected Impact on People with High-Risk Conditions'
About the event
Speakers on the night will share insight on the new era of cancer prevention trials. Research and clinical trials in cancer prevention are critical for improving patient outcomes and reducing pressure on healthcare systems. The new field of precision prevention exploits biological insights into risk factors and cancer development to precisely target interventions to individuals at high risk, with the aim of delaying or preventing cancer. Oxford University hosts the UK's first and only Cancer Research UK-accredited trials centre specialising in cancer precision prevention studies and is changing the way that these trials are run. Compared to traditional cancer prevention trials, precision prevention trials are more focused, smaller and shorter, and thus more attractive to commercial timelines. This event will highlight the innovations in cancer prevention trials and explore the impact on pharma and people affected by a high-risk condition.
Outline Programme:
17:00 – 17:30 - Registration & networking
17:30 – 19:00 – Presentations & discussions:
- 30-minute scene setting keynote, Prof Sarah Blagden
- 60-minute chaired discussion with speakers representing Big Pharma, Small Pharma, Regulatory expert, Patient, to include 5-minute stand-alone intro from each speaker and audience questions. Contributors so far include:
Anna Fry, Senior Manager at Cancer Research UK
Kirsty Wydenbach, Head of Regulatory Strategy at Weatherden
19:00 – 20:00 – Networking, drinks & nibbles